Alnylam Pharmaceuticals, Inc. (ALNY Quick QuoteALNY - Free Report) was a big mover last session, as the company saw its shares jump a little above 16% on the day. The upside was driven by the news that its competing drug candidate, patisiran, is scheduled to announce its phase 3 results soon. Also, this led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 29% in the past one-month time frame.

The company has seen a mixed track record of two positive and five negative estimate revisions in the past 30 days, while the Zacks Consensus Estimate moved lower over the same timeframe. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Alnylam Pharmaceuticals currently has a Zacks Rank #3 (Hold).

Alnylam Pharmaceuticals, Inc. Price

Alnylam Pharmaceuticals, Inc. Price | Alnylam Pharmaceuticals, Inc. Quote

A top-ranked stock in the Medical-Biomedical and Genetics industry is Aeglea BioTherapeutics sporting a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Is ALNY going up? Or down? Predict to see what others think: Up or Down

5 Trades Could Profit "Big-League" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.See these buy recommendations now >>